HS-10542

Phase 2

Hansoh Pharmaceutical Group Co Limited/ADR (HNPHY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

HNPHYPhase 2

HS-10542 Phase 2 Est. Readout

HS-10542• Paroxysmal Nocturnal Hemoglobinuria50

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

3 competitors in Paroxysmal Nocturnal Hemoglobinuria

Drug Information

Target Indication

Paroxysmal Nocturnal Hemoglobinuria

Clinical Trial

NCT07470762

Last updated: 3/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

HNPHY

Hansoh Pharmaceutical Group Co Limited/ADR

Biotechnology•North America•NASDAQ

Related Pipeline

HS-20093Phase 3

Metastasis Castration Resistant Prostate Cancer(mCRPC)

Gemcitabine combined with docetaxelPhase 3

Osteosarcoma

AlmonertinibPhase 3

Lung Cancer

TopotecanPhase 3

Small Cell Lung Cancer

HS-10566Phase 2

High-risk Non-muscle-invasive Bladder Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts